HRP20210891T1 - Liječenje bolesti presatka protiv primatelja u pacijenata s transplantacijom - Google Patents

Liječenje bolesti presatka protiv primatelja u pacijenata s transplantacijom Download PDF

Info

Publication number
HRP20210891T1
HRP20210891T1 HRP20210891TT HRP20210891T HRP20210891T1 HR P20210891 T1 HRP20210891 T1 HR P20210891T1 HR P20210891T T HRP20210891T T HR P20210891TT HR P20210891 T HRP20210891 T HR P20210891T HR P20210891 T1 HRP20210891 T1 HR P20210891T1
Authority
HR
Croatia
Prior art keywords
compound
conditioning
use according
day
days
Prior art date
Application number
HRP20210891TT
Other languages
English (en)
Croatian (hr)
Inventor
Peter Gergely
Kazuhiko Kuriyama
Original Assignee
Priothera Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Priothera Limited filed Critical Priothera Limited
Publication of HRP20210891T1 publication Critical patent/HRP20210891T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01B—SOIL WORKING IN AGRICULTURE OR FORESTRY; PARTS, DETAILS, OR ACCESSORIES OF AGRICULTURAL MACHINES OR IMPLEMENTS, IN GENERAL
    • A01B1/00—Hand tools
    • A01B1/02—Spades; Shovels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Vascular Medicine (AREA)
  • Environmental Sciences (AREA)
  • Cardiology (AREA)
  • Mechanical Engineering (AREA)
  • Soil Sciences (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20210891TT 2013-02-20 2014-02-18 Liječenje bolesti presatka protiv primatelja u pacijenata s transplantacijom HRP20210891T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361766830P 2013-02-20 2013-02-20
PCT/IB2014/059067 WO2014128611A1 (en) 2013-02-20 2014-02-18 Treatment of graft versus host disease in transplant patients
EP14708330.7A EP2958624B1 (en) 2013-02-20 2014-02-18 Treatment of graft versus host disease in transplant patients

Publications (1)

Publication Number Publication Date
HRP20210891T1 true HRP20210891T1 (hr) 2021-07-23

Family

ID=50236228

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210891TT HRP20210891T1 (hr) 2013-02-20 2014-02-18 Liječenje bolesti presatka protiv primatelja u pacijenata s transplantacijom

Country Status (23)

Country Link
US (2) US20160000811A1 (https=)
EP (1) EP2958624B1 (https=)
JP (2) JP6441822B2 (https=)
KR (1) KR102165514B1 (https=)
CN (1) CN105007981B (https=)
AU (1) AU2014220377B2 (https=)
BR (1) BR112015019197A2 (https=)
CA (1) CA2898565C (https=)
CY (1) CY1124191T1 (https=)
DK (1) DK2958624T3 (https=)
EA (1) EA030783B1 (https=)
ES (1) ES2873181T3 (https=)
HR (1) HRP20210891T1 (https=)
HU (1) HUE054330T2 (https=)
LT (1) LT2958624T (https=)
MX (1) MX369631B (https=)
PL (1) PL2958624T3 (https=)
PT (1) PT2958624T (https=)
RS (1) RS61933B1 (https=)
SI (1) SI2958624T1 (https=)
SM (1) SMT202100334T1 (https=)
TW (1) TWI648050B (https=)
WO (1) WO2014128611A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017153889A1 (en) * 2016-03-08 2017-09-14 Novartis Ag Treatment of hematopoietic stem cell transplant patients
CN112512516A (zh) * 2018-07-27 2021-03-16 普瑞奥治疗有限公司 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂
CN117177748A (zh) * 2020-11-04 2023-12-05 浩康生物系统公司 用于异基因造血干细胞移植的方法
AU2021424131A1 (en) 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
EP4248958A3 (en) 2021-01-28 2024-01-03 Priothera SAS Methods of treatment with s1p receptor modulators
MX2024010047A (es) 2022-02-16 2024-08-26 Priothera Sas Metodos de tratamiento con celulas car en combinacion con moduladores del receptor s1p.
EP4282407A1 (en) 2022-05-27 2023-11-29 Priothera SAS Treatment of cancer with s1p receptor agonists
WO2025109119A1 (en) 2023-11-22 2025-05-30 Priothera Sas Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1011694A4 (en) * 1996-11-15 2000-11-15 Baxter Int TREATMENT FOR ALLOGENIC STEM CELL TRANSPLANTATION
US6383481B1 (en) 1998-03-30 2002-05-07 Japan Immunoresearch Laboratories Co., Ltd. Method for transplantation of hemopoietic stem cells
JPH11343242A (ja) * 1998-03-30 1999-12-14 Otsuka Pharmaceut Co Ltd 造血幹細胞移植用剤
MXPA04002679A (es) * 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
KR101003877B1 (ko) * 2002-09-19 2010-12-30 교린 세이야꾸 가부시키 가이샤 아미노알코올 유도체와 그 부가염 및 면역 억제제
CN101014329B (zh) * 2004-07-16 2010-09-08 杏林制药株式会社 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物
WO2006073126A1 (ja) * 2005-01-06 2006-07-13 Kissei Pharmaceutical Co., Ltd. 慢性移植片対宿主症におけるドライアイの予防および治療剤
ES2686424T5 (es) 2010-05-04 2023-03-27 Yeda Res & Dev Inmunoterapia con células alogénicas redireccionadas
EP2566473B1 (en) * 2010-05-06 2016-01-06 Novartis AG Dosage regimen of diaryl sulfide derivatives

Also Published As

Publication number Publication date
WO2014128611A1 (en) 2014-08-28
SI2958624T1 (sl) 2021-07-30
CA2898565C (en) 2023-01-24
KR20150118149A (ko) 2015-10-21
TW201511751A (zh) 2015-04-01
HUE054330T2 (hu) 2021-09-28
CN105007981A (zh) 2015-10-28
JP2016509050A (ja) 2016-03-24
JP6441822B2 (ja) 2018-12-19
EP2958624A1 (en) 2015-12-30
PT2958624T (pt) 2021-06-11
CN105007981B (zh) 2020-07-21
US20160000811A1 (en) 2016-01-07
PL2958624T3 (pl) 2021-10-04
EP2958624B1 (en) 2021-05-12
JP6633170B2 (ja) 2020-01-22
AU2014220377B2 (en) 2017-05-04
KR102165514B1 (ko) 2020-10-15
US11224604B2 (en) 2022-01-18
CA2898565A1 (en) 2014-08-28
EA030783B1 (ru) 2018-09-28
US20180153911A1 (en) 2018-06-07
EA201591522A1 (ru) 2016-03-31
JP2019059748A (ja) 2019-04-18
SMT202100334T1 (it) 2021-07-12
BR112015019197A2 (pt) 2017-07-18
CY1124191T1 (el) 2022-05-27
ES2873181T3 (es) 2021-11-03
AU2014220377A1 (en) 2015-08-06
TWI648050B (zh) 2019-01-21
RS61933B1 (sr) 2021-07-30
LT2958624T (lt) 2021-08-10
MX369631B (es) 2019-11-14
DK2958624T3 (da) 2021-06-07
MX2015010833A (es) 2016-07-08

Similar Documents

Publication Publication Date Title
HRP20210891T1 (hr) Liječenje bolesti presatka protiv primatelja u pacijenata s transplantacijom
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
JP2016509050A5 (https=)
BR112014018485A8 (pt) Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
BR112015006828A8 (pt) composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
HRP20131083T1 (hr) POSTUPCI PRIMJENE N-(5-terc-BUTILIZOKSAZOL-3-IL)-N&#39;-{4-[7-(2-MORFOLIN-4-ILETOKSI)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-IL]FENIL}UREE U LIJEÄŚENJU PROLIFERATIVNE BOLESTI
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112019005351A2 (pt) terapia combinada com agonistas de cnp de liberação controlada
BR112012022187A2 (pt) tratamento de artrite reumatóide com a combinação de laquinimod e metotrexato
AR095197A1 (es) Combinación de un inhibidor de egfr t790m y un inhibidor de egfr para el tratamiento del cáncer pulmonar de células no pequeñas
BR112012025390B8 (pt) Composto de tetraidrobenzotiofeno ou sal do mesmo e seu uso no tratamento ou prevenção de hiperfosfatemia, bem como composição farmacêutica compreendendo o dito composto
BR112022015727A2 (pt) Métodos para a preparação de uma quitosana reticulada, para a preparação de um sistema de liberação de fármacos, para prevenir, tratar ou melhorar um distúrbio médico e para identificar uma quitosana reticulada, quitosana reticulada, composição, enchimento de tecido mole, curativo para ferimentos ou tecido de reconstrução, nanopartículas, meio de cultura para células ou tecido biológico, uso de quitosana reticulada, e, kit
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
CL2015002627A1 (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
BR112018012765A2 (pt) composição, método para tratamento, prevenção e/ou melhora de uma afecção médica, e, dispositivo mecânico.
BRPI0715609A2 (pt) Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
Witzens-Harig et al. Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting
BR112015014261A8 (pt) composto de danazol, seu uso e formulação farmacêutica compreendendo este
BR112023026356A2 (pt) Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c
HRP20210012T1 (hr) Lijek za liječenje infekcija dijabetičkog stopala